Want to see INAB full AI Analyst Report?
Top Page
IN8bio
(NASDAQ:INAB)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.00
▼(-15.25% Downside)
Action:Reiterated
Date:08/28/26
The score is primarily held down by weak financial performance typical of a development-stage biotech (no revenue, ongoing losses, and negative free cash flow), despite improved loss and cash-burn trends and low leverage. Technicals add pressure with the stock trading below major moving averages and soft momentum. Valuation is hard to assess due to negative earnings and no dividend support.
Positive Factors
Narrowing Net Losses
The reduction in annual losses indicates improving cost discipline and operating control. While IN8bio remains far from profitability, sustaining this trend could extend its runway and improve the efficiency of investment in its clinical pipeline.
Negative Factors
No Product Revenue
The absence of product revenue means the company has no recurring commercial funding engine and remains dependent on clinical progress before meaningful monetization. This leaves results exposed to development delays, trial outcomes and regulatory execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Narrowing Net Losses
The reduction in annual losses indicates improving cost discipline and operating control. While IN8bio remains far from profitability, sustaining this trend could extend its runway and improve the efficiency of investment in its clinical pipeline.
Read all positive factors
IN8bio (INAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.68M
Dividend YieldN/A
Average Volume (3M)43.54K
Price to Earnings (P/E)―
Beta (1Y)1.88
Revenue GrowthN/A
EPS Growth81.87%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.87
Shares Outstanding9,858,383
10 Day Avg. Volume51,779
30 Day Avg. Volume43,544
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside323.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.09
Revenue Forecast (FY)N/A
IN8bio Business Overview & Revenue Model
Company Description
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic...
How the Company Makes Money
IN8bio is a clinical-stage biotech and, as of publicly available disclosures, does not have product sales; its operations are primarily funded through capital raising rather than recurring commercial revenue. Its primary sources of cash historical...
IN8bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -500.00K | -2.50M | 0.00 | -2.50M | 0.00 | 0.00 |
| EBITDA | -16.71M | -16.94M | -26.94M | -27.51M | -27.42M | -13.87M |
| Net Income | -18.67M | -19.44M | -30.44M | -30.01M | -28.52M | -14.65M |
Balance Sheet | ||||||
| Total Assets | 21.75M | 32.28M | 20.94M | 33.71M | 33.04M | 42.22M |
| Cash, Cash Equivalents and Short-Term Investments | 17.96M | 27.09M | 11.12M | 21.28M | 18.18M | 37.02M |
| Total Debt | 2.18M | 2.78M | 5.03M | 4.89M | 5.87M | 2.41M |
| Total Liabilities | 3.38M | 4.72M | 6.47M | 8.77M | 10.31M | 4.04M |
| Stockholders Equity | 18.36M | 27.56M | 14.48M | 24.94M | 22.73M | 38.18M |
Cash Flow | ||||||
| Free Cash Flow | -14.60M | -12.71M | -24.25M | -23.94M | -27.83M | -13.82M |
| Operating Cash Flow | -14.36M | -12.71M | -24.15M | -23.34M | -24.12M | -13.51M |
| Investing Cash Flow | -242.00K | 0.00 | -187.00K | -600.00K | -3.71M | -309.00K |
| Financing Cash Flow | 19.23M | 28.64M | 14.18M | 27.04M | 8.99M | 32.95M |
IN8bio Technical Analysis
Negative
1.18
Price Trends
1.24
Negative
1.38
Negative
1.62
Negative
Market Momentum
-0.01
Negative
41.11
Neutral
46.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INAB, the sentiment is Negative. The current price of 1.18 is above the 20-day moving average (MA) of 1.09, below the 50-day MA of 1.24, and below the 200-day MA of 1.62, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 41.11 is Neutral, neither overbought nor oversold. The STOCH value of 46.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INAB.
IN8bio Risk Analysis
IN8bio disclosed 74 risk factors in its most recent earnings report. IN8bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IN8bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $12.34M | -0.67 | -59.54% | ― | -99.38% | 53.42% | |
50 Neutral | $9.04M | -3.34 | -39.28% | ― | 33.30% | 40.59% | |
46 Neutral | $11.68M | -0.56 | -96.39% | ― | ― | 81.87% | |
46 Neutral | $10.40M | -0.35 | -292.33% | ― | ― | 98.98% |
* Healthcare Sector Average
INAB
IN8bio
1.04
-1.22
-53.98%
ERNA
Eterna Therapeutics
4.74
-29.77
-86.28%
QNRX
Quoin Pharmaceuticals
5.16
-2.34
-31.27%
XBIO
Xenetic Biosciences
3.97
1.12
39.30%
APRE
Aprea Therapeutics
0.86
-0.73
-45.74%
IN8bio Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
IN8bio launches new JonesTrading at-the-market program
Neutral
Jun 1, 2026
On June 1, 2026, IN8bio, Inc. entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC to establish an at-the-market equity offering program for its common stock under its existing Form S-3 shelf registration. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.